Secondary hyperparathyroidism

This study tested a new drug called MT1013 in 115 adults with chronic kidney disease who are on dialysis and have a condition called secondary hyperparathyroidism (high parathyroid hormone). The goal was to see if the drug could safely lower hormone levels by at least 30%. Partic…

This study tests a new drug called SHR6508 in 303 adults on hemodialysis who have secondary hyperparathyroidism, a condition where parathyroid hormone levels get too high. The drug is given as an injection to help control these hormone levels and related minerals like calcium and…

This study tested a new drug called MT1013 in 98 adults on kidney dialysis who have secondary hyperparathyroidism, a condition where parathyroid hormone levels are too high. The goal was to see if the drug is safe and can lower these hormone levels. Participants received either t…

This study tested a new drug called SHR6508 in 498 adults on hemodialysis who have secondary hyperparathyroidism, a condition where the parathyroid glands make too much hormone. The drug is given during dialysis and was compared to an existing oral medication, cinacalcet. The goa…

This study tested a drug called PLS240 in 412 adults with end-stage kidney disease on dialysis who also have overactive parathyroid glands (secondary hyperparathyroidism). Participants received either PLS240 or a placebo intravenously three times a week for 27 weeks, followed by …

This study tested a drug called PLS240 in 362 adults with end-stage kidney disease on dialysis who also have overactive parathyroid glands (secondary hyperparathyroidism). Participants received either PLS240 or a placebo during dialysis three times a week for 27 weeks, followed b…

This study follows adults receiving maintenance hemodialysis for end-stage kidney disease to develop a model that predicts the risk of dying from cardiovascular disease. Researchers will track routine lab results, including how often blood phosphate levels stay in a target range,…

This early-stage study looks at how the experimental drug MT1013 moves through and leaves the body of people on hemodialysis who have secondary hyperparathyroidism. Six participants will receive a single dose, and researchers will measure radioactivity in blood, urine, and stool …

This completed Phase 1 study looked at how a radioactive form of the drug SHR6508 is processed and eliminated in 5 Chinese adults on hemodialysis who have secondary hyperparathyroidism. The main goal was to measure how much radioactivity ends up in urine and stool, and to identif…

This study looked at 167 adults with chronic kidney disease on either hemodialysis or peritoneal dialysis to compare their blood levels of calcium, phosphorus, and other minerals linked to bone health. The goal was to see if one dialysis method is associated with fewer mineral an…